Modality
Fusion Protein
MOA
BTKi
Target
WEE1
Pathway
NF-κB
FSGSWilmsGBM
Development Pipeline
Preclinical
~Jan 2014
→ ~Apr 2015
Phase 1
~Jul 2015
→ ~Oct 2016
Phase 2
Jan 2017
→ Nov 2031
Phase 2Current
NCT04089133
2,549 pts·GBM
2017-01→2031-11·Terminated
2,549 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-11-045.6y awayPh2 Data· GBM
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P2
Termina…
Catalysts
Ph2 Data
2031-11-04 · 5.6y away
GBM
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04089133 | Phase 2 | GBM | Terminated | 2549 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| NVO-7872 | Novo Nordisk | NDA/BLA | B7-H3 | |
| NVO-6275 | Novo Nordisk | Phase 1 | SMN2 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| Lisorapivir | Takeda | Preclinical | WRN | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| Ivosotorasib | Vertex Pharma | Preclinical | CD38 | |
| MRN-8133 | Moderna | Phase 2 | PD-1 | |
| ARG-314 | Argenx | Approved | Aβ |